Randomized phase I trial HIV-CORE 003: Depletion of serum amyloid P component and immunogenicity of DNA vaccination against HIV-1
<strong>Background</strong> The failure of DNA vaccination in humans, in contrast to its efficacy in some species, is unexplained. Observational and interventional experimental evidence suggests that DNA immunogenicity may be prevented by binding of human serum amyloid P component (SAP)....
Main Authors: | Borthwick, N, Lane, T, Moyo, N, Crook, A, Shim, J, Baines, I, Wee, E, Hawkins, P, Gillmore, J, Hanke, T, Pepys, M |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Public Library of Science
2018
|
Similar Items
-
Long-term follow up of human T-cell responses to conserved HIV-1 regions elicited by DNA/simian adenovirus/MVA vaccine regimens
by: Moyo, N, et al.
Published: (2017) -
Priming with recombinant BCG expressing novel HIV-1 conserved mosaic immunogens and boosting with recombinant ChAdOx1 is safe, stable, and elicits HIV-1-specific T-cell responses in BALB/c mice
by: Hanke, T, et al.
Published: (2019) -
Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis.
by: Richards, D, et al.
Published: (2018) -
Tetravalent Immunogen Assembled from Conserved Regions of HIV-1 and Delivered as mRNA Demonstrates Potent Preclinical T-Cell Immunogenicity and Breadth
by: Nathifa Moyo, et al.
Published: (2020-07-01) -
Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component.
by: Kolstoe, SE, et al.
Published: (2009)